Indication

HER2-activating Mutation

1 clinical trial

1 product

Clinical trial

Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions

Status: Terminated, Estimated PCD: 2021-04-09

Product